Sensitive to (transplant) rejection

An experimental screening method, developed by Emory and Georgia Tech scientists, aims to detect immune rejection of a transplanted organ earlier and without a biopsy Read more

CAPTCHA some cancer cells

Lee Cooper and colleagues explore crowdsourcing in pathology -- using slides from the Cancer Genome Read more

Bird flu shuffle probes viral compatibility

The good news is that packaging signals on the H5 and H7 viral RNA genomes are often incompatible with the H3N2 viruses. But mix and match still occurred at a low level, particularly with Read more

LDL cholesterol

When cardiac risk biomarkers will become really useful (and save money?)

The news is awash in studies of cholesterol-lowering statins and a much-anticipated (and expensive) class of drugs called PCSK9 inhibitors. Clinical trials show that now-generic (and cheap) statins reduce the risk of heart attack and stroke, although some patients report they can’t tolerate them. The data is still to come showing whether PCSK9 inhibitors have the same risk-lowering effect, as opposed to their effects on LDL cholesterol, which are robust.

When /if doctors have to start deciding who should take drugs that cost thousands of dollars a year and who shouldn’t, biomarkers may come in handy. How about a panel of markers like the one studied by Emory cardiologist Arshed Quyyumi, MD and colleagues?

At the recent American College of Cardiology meeting in Chicago, research fellow Salim Hayek, MD reported on a five-marker panel and how it could predict the risk of cardiovascular events (that is: death, heart attack, hospitalization for heart failure) in a group of patients who underwent cardiac catheterization at Emory hospitals.

The five biomarkers are: C-reactive protein (CRP, measures inflammation), suPAR (soluble urokinase-type plasminogen activator receptor or suPAR, predicts kidney disease), fibrin degradation products (FDP: blood coagulation), heat-shock protein-70 (HSP70, cellular stress) and troponin (hs-TnI, cardiac muscle damage). Data on three of these were published in 2013.

The Emory team keeps adding more biomarkers, and the ability of the accumulated information to add to what doctors can figure out easily — the Framingham score and its successors — becomes stronger.

Posted on by Quinn Eastman in Heart Leave a comment

Cholesterol levels improve with nut consumption

Improvements in blood cholesterol levels are linked with eating nuts, according to this week’s Archives of Internal Medicine.

Nuts are good for your heart

Authors writing in the journal say that dietary interventions to lower blood cholesterol concentrations and to modify blood lipoprotein levels are the cornerstone of prevention and treatment plans for coronary heart disease.

Nuts are rich in plant proteins, fats (especially unsaturated fatty acids), dietary fiber, minerals, vitamins and other compounds, such as antioxidants and phytoesterols. The contents of nuts are a focus because of the potential to reduce coronary heart disease risk and to lower blood lipid – fat and cholesterol – levels.

Emory University’s Cheryl Williams, RD, LD, clinical nutritionist, Emory Heart & Vascular Center, Emory HeartWise Cardiac Risk Reduction Program, says nuts are among the heart healthiest whole foods as they provide a variety of health promoting compounds such as dietary fiber, vitamins (vitamin E), minerals (selenium), antioxidants and phytoesterols.

While most of the calories provided from nuts come from fat, notes Williams, it is mostly unsaturated fats (mono and polyunsaturated), which have been shown to help lower elevated serum cholesterol, and to some extent triglyceride levels (via omega 3 fatty acids provided from walnuts).

Read more

Posted on by Jennifer Johnson in Uncategorized Leave a comment